down arrow

HilleVax, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US43157M1027
USD
2.09
-0.01 (-0.48%)

Sep 18

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

1.342.17
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Jun 2025)

FII

23.60%

Held by 42 FIIs

DII

6.05%

Held by 20 DIIs

Promoter

56.06%

How big is HilleVax, Inc.?

22-Jun-2025

As of Jun 18, HilleVax, Inc. has a market capitalization of 92.76 million and reported net sales of 0.00 million with a net profit of -106.50 million over the last four quarters. Shareholder's funds are 154.49 million, and total assets are 192.69 million.

Market Cap: As of Jun 18, HilleVax, Inc. has a market capitalization of 92.76 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, HilleVax, Inc. reported net sales of 0.00 million and a net profit of -106.50 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 154.49 million, while total assets were reported at 192.69 million.

Read More

What does HilleVax, Inc. do?

22-Jun-2025

HilleVax, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry with a market cap of $92.76 million and a net profit of -$6 million as of March 2025. It has a P/E ratio of NA, a dividend yield of 0.00%, and a negative return on equity of -47.47%.

Overview: <BR>HilleVax, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Market cap: USD 92.76 Million <BR>Net Profit: -6 Million (Quarterly Results - Mar 2025)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -47.47% <BR>Price to Book: 0.61 <BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is HilleVax, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, HilleVax, Inc. shows a mildly bullish trend overall, despite mixed signals from indicators and underperformance compared to the S&P 500.

As of 2 September 2025, the technical trend for HilleVax, Inc. has changed from bullish to mildly bullish. The weekly and monthly MACD indicators are both mildly bullish, while the daily moving averages also indicate a mildly bullish stance. However, the Bollinger Bands present a mixed view with the weekly being mildly bullish and the monthly mildly bearish. The KST and Dow Theory show bearish signals on the weekly and monthly time frames, and the OBV is mildly bearish on the weekly. <BR><BR>In terms of performance, HilleVax has returned 15.47% over the past year, compared to the S&P 500's 17.14%, indicating underperformance relative to the benchmark. Overall, the current technical stance is mildly bullish, but with caution due to mixed signals from other indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 105 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.05

stock-summary
Return on Equity

-30.09%

stock-summary
Price to Book

0.71

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.37%
0%
12.37%
6 Months
19.43%
0%
19.43%
1 Year
16.76%
0%
16.76%
2 Years
-85.5%
0%
-85.5%
3 Years
-90.39%
0%
-90.39%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

HilleVax, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-22.99%
EBIT to Interest (avg)
-42.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.66
EV to EBIT
0.70
EV to EBITDA
0.73
EV to Capital Employed
11.17
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1593.22%
ROE (Latest)
-47.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 26 Schemes (14.29%)

Foreign Institutions

Held by 42 Foreign Institutions (23.6%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 86.98% vs -45.88% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.50",
          "val2": "-33.90",
          "chgp": "80.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-8.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.30",
          "val2": "-40.70",
          "chgp": "86.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -19.17% vs 22.65% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-103.80",
          "val2": "-131.20",
          "chgp": "20.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "2.40",
          "chgp": "-37.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-50.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-147.30",
          "val2": "-123.60",
          "chgp": "-19.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.50
-33.90
80.83%
Interest
0.00
0.70
-100.00%
Exceptional Items
0.00
-8.20
100.00%
Consolidate Net Profit
-5.30
-40.70
86.98%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 86.98% vs -45.88% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-103.80
-131.20
20.88%
Interest
1.50
2.40
-37.50%
Exceptional Items
-50.20
0.00
Consolidate Net Profit
-147.30
-123.60
-19.17%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -19.17% vs 22.65% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About HilleVax, Inc. stock-summary
stock-summary
HilleVax, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."